Structural & Congenital Heart Disease

The FDA has expanded its indication for TAVR to low-risk patients, the agency announced August 16, approving a handful of valves for an intervention that was previously limited to intermediate- and high-risk patients.

Mental illnesses including developmental and mood disorders are prevalent in adolescents and adults with CHD, an American Journal of Cardiology study found, suggesting mental health care might be a beneficial factor in comprehensive treatment.

Surgery doesn’t improve survival in patients with isolated severe tricuspid regurgitation, researchers have found.

Newly diagnosed HF patients with concomitant mitral regurgitation can expect more admissions, longer hospital stays and pricier medical bills than HF patients without MR, according to an analysis published in the American Journal of Cardiology.

White patients are recommended for three of the most common structural heart disease interventions more often than their black and Hispanic counterparts, according to a recent study published in the Journal of the American Heart Association, but procedural outcomes are similar among the groups.

Reports of burst balloons with the Sapien 3 Ultra heart valve have resulted in an urgent safety notice from the manufacturer and a Canadian recall of the system.

Abbott’s fourth-generation MitraClip device was approved by the FDA July 15 to treat mitral regurgitation (MR) in a wider population of patients, the company announced this week.

Patients with aortic stenosis who undergo SAVR live on average 1.9 years less than the general population, according to a study published in the July issue of the Journal of the American College of Cardiology.

CMS on June 21 issued its finalized national coverage determination for TAVR—one that reportedly offers greater flexibility for hospitals and providers.

A novel robotic catheter could simplify valve procedures while allowing cardiac surgeons to complete multiple interventions within the same time frame, according to research presented at TVT 2019 in Chicago.

Research presented at TVT 2019 in Chicago last week suggests a transcarotid approach to transcatheter aortic valve replacement is favorable for patients unable to tolerate femoral access, topping both transapical and transaortic approaches as the preferable route for alternate-access TAVR.  

Physicians are facing a new issue as TAVR expands to younger populations—an increased incidence of bicuspid aortic stenosis.